{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:06:16Z","timestamp":1775106376479,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01688-z","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:55:19Z","timestamp":1772456119000},"page":"2031-2045","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE Study"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05272150","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-9165","authenticated-orcid":false,"given":"Andrew","family":"Alexis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"McMichael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-2598","authenticated-orcid":false,"given":"Neelam","family":"Vashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-1024","authenticated-orcid":false,"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-5515","authenticated-orcid":false,"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Alkousakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5175-3016","authenticated-orcid":false,"given":"Olivia","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Lester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian O.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9626-6863","authenticated-orcid":false,"given":"Geeta","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3192-3564","authenticated-orcid":false,"given":"Chesahna","family":"Kindred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6663-2471","authenticated-orcid":false,"given":"Pearl","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"8","key":"1688_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2007.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1688_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jaad.2024.12.002","volume":"92","author":"B Smith","year":"2025","unstructured":"Smith B, Kim YJ, Tung JK. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2025;92(4):917\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.002.","journal-title":"J Am Acad Dermatol"},{"key":"1688_CR3","doi-asserted-by":"publisher","unstructured":"Yadav G, Yeung J, Miller-Monthrope et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. Dermatol Ther (Heidelb). 2022;12(11):2401\u201313. https:\/\/doi.org\/10.1007\/s13555-022-00811-0.","DOI":"10.1007\/s13555-022-00811-0"},{"issue":"4","key":"1688_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/ijd.17651","volume":"64","author":"M-A Gkini","year":"2025","unstructured":"Gkini M-A, Nakamura M, Alexis AF, et al. Psoriasis in people with skin of color: an evidence-based update. Int J Dermatol. 2025;64(4):667\u201377. https:\/\/doi.org\/10.1111\/ijd.17651.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1688_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jaad.2017.02.042","volume":"77","author":"M Abrouk","year":"2017","unstructured":"Abrouk M, Lee K, Brodsky M, et al. Ethnicity affects the presenting severity of psoriasis. J Am Acad Dermatol. 2017;77(1):180\u20132. https:\/\/doi.org\/10.1016\/j.jaad.2017.02.042.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1688_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000528945","volume":"239","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Bohannan B, Mburu S, et al. Patient perspectives on psoriatic disease burden: results from the Global Psoriasis and Beyond Survey. Dermatology. 2023;239(4):621\u201334. https:\/\/doi.org\/10.1159\/000528945.","journal-title":"Dermatology"},{"issue":"5","key":"1688_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/acr.23896","volume":"72","author":"D Sumpton","year":"2020","unstructured":"Sumpton D, Kelly A, Tunnicliffe DJ, et al. Patients\u2019 perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies. Arthritis Care Res (Hoboken). 2020;72(5):711\u201322. https:\/\/doi.org\/10.1002\/acr.23896.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1688_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715839","volume":"12","author":"H Zhang","year":"2021","unstructured":"Zhang H, Yang Z, Tang K, et al. Stigmatization in patients with psoriasis: a mini review. Front Immunol. 2021;12:715839. https:\/\/doi.org\/10.3389\/fimmu.2021.715839.","journal-title":"Front Immunol"},{"issue":"7","key":"1688_CR9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/jdv.17188","volume":"35","author":"R Sommer","year":"2021","unstructured":"Sommer R, Augustin M, Hilbring C, et al. Significance of chronic pruritus for intrapersonal burden and interpersonal experiences of stigmatization and sexuality in patients with psoriasis. J Eur Acad Dermatol Venereol. 2021;35(7):1553\u201361. https:\/\/doi.org\/10.1111\/jdv.17188.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2S","key":"1688_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12788\/cutis.0038","volume":"106","author":"MN Nicholas","year":"2020","unstructured":"Nicholas MN, Chan AR, Hessami-Booshehri M. Psoriasis in patients of color: differences in morphology, clinical presentation, and treatment. Cutis. 2020;106(2S):7\u201310. https:\/\/doi.org\/10.12788\/cutis.0038.","journal-title":"Cutis"},{"issue":"5","key":"1688_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00403-022-02507-z","volume":"315","author":"S Narla","year":"2023","unstructured":"Narla S, Heath CR, Alexis A, et al. Racial disparities in dermatology. Arch Dermatol Res. 2023;315(5):1215\u201323. https:\/\/doi.org\/10.1007\/s00403-022-02507-z.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"1688_CR12","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.36849\/JDD.7090","volume":"21","author":"A Alexis","year":"2022","unstructured":"Alexis A, Woolery-Lloyd H, Andriessen A, et al. Evolving concepts in psoriasis: special considerations for patients with skin of color, skin barrier dysfunction, and the role of adjunctive skin care. J Drugs Dermatol. 2022;21(10):1054\u201360. https:\/\/doi.org\/10.36849\/JDD.7090.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"1688_CR13","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jaad.2020.02.025","volume":"83","author":"S Amico","year":"2020","unstructured":"Amico S, Barnetche T, Dequidt L, et al. on behalf of FHU ACRONIM (F\u00e9d\u00e9ration Hospitalo-Universitaire Aquitaine\u2019s Care and Research Organisation for Inflammatory and Immune-Mediated Diseases). Characteristics of postinflammatory hyper- and hypopigmentation in patients with psoriasis: a survey study. J Am Acad Dermatol. 2020;83(4):1188\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2020.02.025.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1688_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jaad.2021.02.010","volume":"86","author":"H-Y Chiu","year":"2022","unstructured":"Chiu H-Y, Chang Liao N-F, Hui RC, et al. Measurement and prediction of the severity of postinflammatory dyspigmentation after resolution of psoriatic plaques in patients treated with biologic therapy. J Am Acad Dermatol. 2022;86(3):642\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.010.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1688_CR15","first-page":"20","volume":"3","author":"EC Davis","year":"2010","unstructured":"Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20\u201331.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"1688_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","volume":"19","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Alexis AF. Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups. Am J Clin Dermatol. 2018;19(3):405\u201323. https:\/\/doi.org\/10.1007\/s40257-017-0332-7.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1688_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2310\/7750.2009.08077","volume":"13","author":"S Taylor","year":"2009","unstructured":"Taylor S, Grimes P, Lim J, et al. Postinflammatory hyperpigmentation. J Cutan Med Surg. 2009;13(4):183\u201391. https:\/\/doi.org\/10.2310\/7750.2009.08077.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1688_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamadermatol.2024.5103","volume":"161","author":"A Alexis","year":"2025","unstructured":"Alexis A, McMichael A, Vashi N, et al. Improving diversity in a novel psoriasis study: VISIBLE as a framework for clinical trial quality improvement. JAMA Dermatol. 2025;161(3):256\u201364. https:\/\/doi.org\/10.1001\/jamadermatol.2024.5103.","journal-title":"JAMA Dermatol"},{"key":"1688_CR19","first-page":"33","volume":"2","author":"TB Fitzpatrick","year":"1975","unstructured":"Fitzpatrick TB. Soleil et peau. J Med Esthet. 1975;2:33\u20134.","journal-title":"J Med Esthet"},{"issue":"6","key":"1688_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archderm.124.6.869","volume":"124","author":"TB Fitzpatrick","year":"1988","unstructured":"Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124(6):869\u201371. https:\/\/doi.org\/10.1001\/archderm.124.6.869.","journal-title":"Arch Dermatol"},{"key":"1688_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1001\/jamadermatol.2025.1836","volume":"161","author":"A Alexis","year":"2025","unstructured":"Alexis A, McMichael A, Soung J, et al. Guselkumab for moderate to severe psoriasis across all skin tones: cohort A of the VISIBLE randomized clinical trial. JAMA Dermatol. 2025;161:901\u201311. https:\/\/doi.org\/10.1001\/jamadermatol.2025.1836.","journal-title":"JAMA Dermatol"},{"key":"1688_CR22","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/jamadermatol.2025.1849","volume":"161","author":"A McMichael","year":"2025","unstructured":"McMichael A, Shahriari M, Stein Gold L, et al. Guselkumab for moderate to severe scalp psoriasis across all skin tones: cohort B of the VISIBLE randomized clinical trial. JAMA Dermatol. 2025;161:912\u201322. https:\/\/doi.org\/10.1001\/jamadermatol.2025.1849.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1688_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jid.2019.11.003","volume":"140","author":"BCK Ly","year":"2020","unstructured":"Ly BCK, Dyer EB, Feig JL, et al. Research techniques made simple: cutaneous colorimetry: a reliable technique for objective skin color measurement. J Invest Dermatol. 2020;140(1):3-12.e1. https:\/\/doi.org\/10.1016\/j.jid.2019.11.003.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"1688_CR24","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jamadermatol.2015.0351","volume":"151","author":"M Wilkes","year":"2015","unstructured":"Wilkes M, Wright CY, du Plessis JL, et al. Fitzpatrick skin type, individual typology angle, and melanin index in an African population: steps toward universally applicable skin photosensitivity assessments. JAMA Dermatol. 2015;151(8):902\u20133. https:\/\/doi.org\/10.1001\/jamadermatol.2015.0351.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1688_CR25","first-page":"377","volume":"3","author":"R Balkrishnan","year":"2004","unstructured":"Balkrishnan R, Kelly AP, McMichael A, et al. Improved quality of life with effective treatment of facial melasma: the PIGMENT trial. J Drugs Dermatol. 2004;3(4):377\u201381.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1688_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/1346-8138.14172","volume":"45","author":"MBC Maymone","year":"2018","unstructured":"Maymone MBC, Neamah HH, Secemsky EA, et al. Correlating the Dermatology Life Quality Index and Skin Discoloration Impact Evaluation Questionnaire tools in disorders of hyperpigmentation. J Dermatol. 2018;45(3):361\u20132. https:\/\/doi.org\/10.1111\/1346-8138.14172.","journal-title":"J Dermatol"},{"issue":"4","key":"1688_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2014oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344. https:\/\/doi.org\/10.1159\/000250839.","journal-title":"Dermatologica"},{"issue":"2","key":"1688_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000051731","volume":"203","author":"D Tha\u00e7i","year":"2001","unstructured":"Tha\u00e7i D, Daiber W, Boehncke WH, et al. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology. 2001;203(2):153\u20136. https:\/\/doi.org\/10.1159\/000051731.","journal-title":"Dermatology"},{"issue":"1","key":"1688_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1610-0387.2010.07412.x","volume":"9","author":"G Wozel","year":"2011","unstructured":"Wozel G, Klein E, Mrowietz U, et al. Scalp psoriasis. JDDG J Dtsch Dermatol Ges. 2011;9(1):70\u20134. https:\/\/doi.org\/10.1111\/j.1610-0387.2010.07412.x. (English, German.).","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"3","key":"1688_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"key":"1688_CR31","unstructured":"HealthMeasures. https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis. Accessed 11 July 2025."},{"issue":"5 Suppl 1","key":"1688_CR32","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","volume":"45","author":"D Cella","year":"2007","unstructured":"Cella D, Yount S, Rothrock N, PROMIS Cooperative Group, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care. 2007;45(5 Suppl 1):S3\u201311. https:\/\/doi.org\/10.1097\/01.mlr.0000258615.42478.55.","journal-title":"Med Care"},{"issue":"11","key":"1688_CR33","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A, PROMIS Cooperative Group, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010;63(11):1179\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.011.","journal-title":"J Clin Epidemiol"},{"key":"1688_CR34","unstructured":"Demirli R, Otto P, Viswanathan R, et al. RBX\u00ae technology overview. https:\/\/www.canfieldsci.com\/FileLibrary\/RBX%20tech%20overview-LoRz1.pdf. Accessed 11 July 2025."},{"issue":"1","key":"1688_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0536.1996.tb02258.x","volume":"35","author":"A Fullerton","year":"1996","unstructured":"Fullerton A, Fischer T, Lahti A, et al. Guidelines for measurement of skin colour and erythema. A report from the Standardization Group of the European Society of Contact Dermatitis. Contact Dermatitis. 1996;35(1):1\u201310. https:\/\/doi.org\/10.1111\/j.1600-0536.1996.tb02258.x.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"1688_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125(4):659\u201364. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23621.x.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1688_CR37","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40257-017-0333-6","volume":"19","author":"BP Kaufman","year":"2018","unstructured":"Kaufman BP, Aman T, Alexis AF. Postinflammatory hyperpigmentation: epidemiology, clinical presentation, pathogenesis and treatment. Am J Clin Dermatol. 2018;19(4):489\u2013503. https:\/\/doi.org\/10.1007\/s40257-017-0333-6.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1688_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28124839","volume":"28","author":"AM Thawabteh","year":"2023","unstructured":"Thawabteh AM, Jibreen A, Karaman D, et al. Skin pigmentation types, causes and treatment-a review. Molecules. 2023;28(12):4839. https:\/\/doi.org\/10.3390\/molecules28124839.","journal-title":"Molecules"},{"issue":"12","key":"1688_CR39","first-page":"797","volume":"96","author":"S Plensdorf","year":"2017","unstructured":"Plensdorf S, Livieratos M, Dada N. Pigmentation disorders: diagnosis and management. Am Fam Physician. 2017;96(12):797\u2013804.","journal-title":"Am Fam Physician"},{"issue":"5","key":"1688_CR40","first-page":"18","volume":"10","author":"K Darji","year":"2017","unstructured":"Darji K, Varade R, West D, et al. Psychosocial impact of postinflammatory hyperpigmentation in patients with acne vulgaris. J Clin Aesthet Dermatol. 2017;10(5):18\u201323.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"7","key":"1688_CR41","first-page":"19","volume":"7","author":"VD Callender","year":"2014","unstructured":"Callender VD, Alexis AF, Daniels SR, et al. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014;7(7):19\u201331.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"7","key":"1688_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.mpmed.2021.04.010","volume":"49","author":"MK Lakhan","year":"2021","unstructured":"Lakhan MK, Lynch M. Skin pigmentation. Medicine. 2021;49(7):447\u201352. https:\/\/doi.org\/10.1016\/j.mpmed.2021.04.010.","journal-title":"Medicine"},{"issue":"12 Suppl 1","key":"1688_CR43","first-page":"S24","volume":"14","author":"AM Sangha","year":"2021","unstructured":"Sangha AM. Special considerations in the diagnosis and treatment of psoriasis. J Clin Aesthet Dermatol. 2021;14(12 Suppl 1):S24\u20135.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"1688_CR44","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1365-4632.2004.02267.x","volume":"43","author":"NL Lacz","year":"2004","unstructured":"Lacz NL, Vafaie J, Kihiczak NI, et al. Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol. 2004;43(5):362\u20135. https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02267.x.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1688_CR45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/pde.14714","volume":"38","author":"A Blundell","year":"2021","unstructured":"Blundell A, Sachar M, Gabel CK, et al. The scope of health insurance coverage of vitiligo treatments in the United States: implications for health care outcomes and disparities in children of color. Pediatr Dermatol. 2021;38(2):79\u201385. https:\/\/doi.org\/10.1111\/pde.14714.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"1688_CR46","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","volume":"73","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Sheth V, Rodrigues M, et al. on behalf of the Vitiligo Working Group. Vitiligo is not a cosmetic disease. J Am Acad Dermatol. 2015;73(5):883\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2015.07.039.","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"1688_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411289","volume":"24","author":"L Bento-Lopes","year":"2023","unstructured":"Bento-Lopes L, Caba\u00e7o LC, Charneca J, et al. Melanin\u2019s journey from melanocytes to keratinocytes: uncovering the molecular mechanisms of melanin transfer and processing. Int J Mol Sci. 2023;24(14):11289. https:\/\/doi.org\/10.3390\/ijms241411289.","journal-title":"Int J Mol Sci"},{"key":"1688_CR48","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/CCID.S385162","volume":"15","author":"E Markiewicz","year":"2022","unstructured":"Markiewicz E, Karaman-Jurukovska N, Mammone T, et al. Post-inflammatory hyperpigmentation in dark skin: molecular mechanism and skincare implications. Clin Cosmet Investig Dermatol. 2022;15:2555\u201365. https:\/\/doi.org\/10.2147\/CCID.S385162.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"1688_CR49","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00403-022-02493-2","volume":"315","author":"S Chatrath","year":"2023","unstructured":"Chatrath S, Bradley L, Kentosh J. Dermatologic conditions in skin of color compared to white patients: similarities, differences, and special considerations. Arch Dermatol Res. 2023;315(5):1089\u201397. https:\/\/doi.org\/10.1007\/s00403-022-02493-2.","journal-title":"Arch Dermatol Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01688-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:34Z","timestamp":1775101114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01688-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01688-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Alexis has received grants (funds to institution) from AbbVie, Amgen, Arcutis, Castle, Dermavant, Genentech, Incyte, and LEO; has served on an advisory board or consulted for AbbVie, Allergan, Almirall, Alphyn, Alumis, Amgen, Apogee, Arcutis, Bausch Health, Beiersdorf, Boehringer Ingelheim, Botanix, Bristol Myers Squibb, Canfield, Castle, Dermavant, Eli Lilly, Galderma, Genentech, HairDays, Incyte, Johnson & Johnson, LEO, L\u2019Or\u00e9al, Novartis, Ortho, Oruka, Pfizer, Sanofi-Regeneron, Swiss American, Symrise, UCB, Veradermics, and VisualDx; has served as a speaker for Aerolase, Johnson & Johnson, L\u2019Or\u00e9al, Regeneron, Sanofi-Genzyme, and Scientis; has received royalties from Elsevier, Springer, Wiley-Blackwell, and Wolters Kluwer Health; and has received equipment from Aerolase. Amy McMichael has received grants (funds to institution) and\/or served as consultant\/advisor for AbbVie, Almirall, Arcutis, Bristol Myers Squibb, Eli Lilly, Galderma, Johnson & Johnson, Kenvue, L\u2019Or\u00e9al, Nutrafol, Pfizer, Revian, Sanofi-Genzyme, and UCB. Neelam Vashi has served as a consultant for Biogen, Canfield, Johnson & Johnson, L\u2019Or\u00e9al, Novartis, and Pfizer. Tina Bhutani is currently a principal investigator for studies being sponsored by AbbVie, Castle, CorEvitas, Dermavant, Galderma, Mindera, and Pfizer. She has additional research funding from Novartis and Regeneron. She has served as an advisor for AbbVie, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Leo Pharma, Pfizer, Novartis, Sun, and UCB. Jensen Yeung is a speaker\/consultant\/honoraria\/trialist for AbbVie, Amgen, Anacor, Arcutis, Astella, Bausch, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, Johnson & Johnson, Leo, Medimmune, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun, Takeda, UCB, and Xenon. Katelyn Rowland, Theodore Alkousakis, and Tony Ma are employees of Johnson & Johnson and may own Johnson & Johnson stock\/stock options. Olivia Choi was an employee Johnson & Johnson at the time this work was conducted and is a shareholder of Johnson & Johnson; she is currently an employee of Apogee Therapeutics. Daphne Chan was an employee Johnson & Johnson at the time this work was conducted and is a shareholder of Johnson & Johnson. Jenna Lester serves on the advisory board for Mattice Biosciences and OurX and is a consultant for L\u2019Or\u00e9al and Google. Adrian O. Rodriguez has served as an advisor and\/or speaker for Arcutis, Dermavant, Eli Lilly, EPI Health, Johnson & Johnson, Leo, Novartis, Sciton, Sun, and UCB. He owns stock in Strathspey Crown. Geeta Yadav has reported consultant\/speaker\/advisory board honorarium from AbbVie, Amgen, Aralez, Arcutis, Bausch Health, BioJAMP, Bristol Myers Squibb, Byrdie, Cipher, Galderma, Incyte, Johnson & Johnson, Kenvue, Leo, L\u2019Or\u00e9al, Novartis, Paladin, Pfizer, P&G, Sanofi, Sun Pharma, UCB, and Unilever; and grants, research or clinical trial support from AbbVie, Amgen, Johnson & Johnson, Lilly, Moonlake, and Sanofi. Chesahna Kindred has served as a consultant, advisory board member, and\/or speaker for AbbVie, Johnson & Johnson, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun, and UCB; has served as an investigator and\/or medical board member for AbbVie, Aerolase, Lilly, Pfizer, and Selphyl; and is a journal editor for\n                      Cutis\n                      . Pearl Grimes has served as a clinical investigator and\/or consultant for AbbVie\/Allergan, Clinuvel, Galderma, Incyte, Johnson & Johnson, LaserOptek, L\u2019Or\u00e9al, Medscape, Mother Science, Pfizer, RAPT, SkinBetterScience, and VYNE. Pearl Grimes is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Pearl Grimes was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Susan C. Taylor has received honoraria\/stock options serving as an advisor\/consultant and\/or speaker for AbbVie, Arcutis, Armis, Avita, Beiersdorf, Biorez, Bristol Myers Squibb, Cara, Dior, Eli Lilly, EPI, Evolus, Galderma, GloGetter, Hugel America, Johnson & Johnson, L\u2019Or\u00e9al, Medscape\/WebMD, MJH LifeSciences, Piction Health, Regeneron\/Sanofi, Scientis US, UCB, Vichy, Mercer Strategies (honoraria\/Board of Directors), McGraw-Hill (author\/royalties), editorial board:\n                      Practical Dermatology\n                      ,\n                      Cutis\n                      ,\n                      Archives in Dermatologic Research\n                      ,\n                      British Journal of Dermatology\n                      (peer reviewer); investigator: Concert Pharmaceuticals, Croma-Pharma, Eli Lilly, and Pfizer. Seemal R. Desai serves as a consultant and\/or investigator for a variety of different organizations including Eli Lilly, Galderma, Incyte, Johnson & Johnson, L\u2019Or\u00e9al, Pfizer and others. He also serves in numerous leadership capacities within Dermatology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The VISIBLE study protocol was approved by appropriate institutional review boards (IRBs) or independent ethics committees. The central IRB is Advarra (Columbia, Maryland, USA; registration number 00000971). Prior to any study-related activity, participants provided informed consent in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice and International Council on Harmonisation guidelines, applicable regulatory requirements, and sponsor policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}